Evidence review · from the 250-topic plan
The SELECT decoder: who the cardiovascular claim actually covers
SELECT is the trial behind every “semaglutide prevents heart attacks” headline — and the headline routinely outruns the data. The study enrolled adults 45 and older with established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease) and BMI ≥27, without diabetes, and found a ~20% relative reduction in major adverse cardiovascular events — which in absolute terms ran on the order of 1.5 percentage points over roughly three-plus years, a number-needed-to-treat in the ballpark of 65–70. That's a landmark result for that population, secondary prevention by definition, demonstrated with the approved product. This decoder separates the four claims people make from the one the trial supports — and shows how to use it correctly in the two places it has real power: your cardiology conversation and your insurance appeal.
Who was actually in the room
Over 17,000 participants, every one carrying established cardiovascular disease — a prior MI, prior stroke, or symptomatic PAD — plus age ≥45 and BMI ≥27, with diabetes excluded (that population's cardiovascular story was already told by earlier trials). This is secondary prevention: people whose arteries have already declared themselves. The design choice was rational — events are frequent enough there to measure — and it draws the claim's border in ink: the certificate reads “in patients like these.”
The two ways to say the same result
Relative: semaglutide 2.4 mg cut major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) by about 20% versus placebo. Absolute, in this high-risk group over a mean follow-up around three-plus years: event rates moved on the order of a point and a half — roughly speaking, treat somewhere in the neighborhood of 65–70 such patients for that period to prevent one major event. Both framings are true; marketing prefers the first, medicine budgets with the second, and an honest reader holds both — noting also that in lower-risk people the same relative effect, even if it transferred perfectly, would shrink in absolute terms because there are fewer events to prevent. That's not cynicism; it's how prevention arithmetic works everywhere.
Four claims, one supported
“Semaglutide reduced cardiovascular events in adults with existing heart disease and overweight/obesity” — supported, verbatim the trial. “Semaglutide prevents heart attacks” (unqualified) — an extrapolation wearing a headline; plausible mechanisms, unmeasured population. “Weight-loss drugs protect everyone's heart” — class-and-population double stretch; tirzepatide's cardiovascular files (its own outcome program, the HFpEF work) are separate evidence, not transferable garnish. “Compounded semaglutide gives you SELECT's protection” — the certificate line this site never drops: compounded shares the intended molecule and mechanism; the outcome certificate belongs to the approved product studied. Any seller deploying SELECT in compounded marketing has told you how they read evidence — which is itself audit-relevant information.
Where the decoded result has real power
The cardiology conversation: if you're in or near the enrolled population — prior event, BMI ≥27 — SELECT belongs in your appointment, because it can reorder the risk-benefit of treating your weight from “elective” to “indicated-shaped,” and your cardiologist will know exactly what the trial is. The insurance appeal: per the appeal anatomy, SELECT is the citation that reframes a weight-exclusion denial into a cardiovascular-treatment argument — when your chart matches the population; cited off-population it's wallpaper, and reviewers know the difference. The shopping decision: for budget-driven molecule choice, SELECT is semaglutide's distinguishing asset over tirzepatide's higher averages — one of the three honest reasons the $119 floor keeps winning shoppers whose charts rhyme with the trial's. The audited semaglutide floor ↗
FAQ
Who does the SELECT trial's result apply to?
Adults 45+ with established cardiovascular disease (prior heart attack, stroke, or symptomatic PAD) and BMI ≥27, without diabetes — secondary prevention; benefit outside that population is extrapolation, not measurement.
How big was SELECT's benefit really?
About a 20% relative reduction in major cardiovascular events — roughly 1.5 percentage points absolute over three-plus years in this high-risk group, an NNT on the order of 65–70.
Does compounded semaglutide provide SELECT's heart protection?
It shares the intended molecule and mechanism; the outcome certificate belongs to the approved product the trial studied — a distinction honest programs state and marketing tends to smudge.
Can SELECT help my insurance appeal?
Powerfully — when your chart matches the enrolled population, it reframes weight-drug denials as cardiovascular-treatment questions; cited off-population it persuades no reviewer.
Sources
- SELECT trial primary publication — population, endpoints, relative and absolute results.
- Wegovy prescribing information — the cardiovascular indication's population language.
- Appeal-anatomy and molecule-choice companion analyses; audited pricing — the open dataset.